We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bosch Healthcare Presents Vivalytic Point-of-Care PCR System

By LabMedica International staff writers
Posted on 13 Nov 2023
Print article
Image: For the first time, Bosch is organizing a panel discussion with Vivalytic (Photo courtesy of Bosch Healthcare)
Image: For the first time, Bosch is organizing a panel discussion with Vivalytic (Photo courtesy of Bosch Healthcare)

Bosch Healthcare Solutions (Waiblingen, Germany) is present at this year’s MEDICA to showcase new tests and its universal platform for molecular diagnostics at the point of care. The MEDICA is an annual international trade fair for the medical industry. At the trade fair, exhibitors from all over the world present their latest products, services, and technologies in the fields of medicine, health care, and nursing. MEDICA is an important platform for the exchange of knowledge and experience between professionals in the industry, including doctors, nurses, medical technicians, and healthcare managers. In addition to the exhibition, various forums and conferences are held each year, where experts from different areas of the medical industry give presentations and lead discussions. These forums provide a great opportunity for professionals to learn about the latest trends and developments in their respective fields and to exchange ideas with other experts.

This year, for the first time and exclusively, Bosch Healthcare Solutions is organizing a panel discussion with Vivalytic, and to discuss the topic of laboratory diagnostics at the point of care with experts from various industries. Particular importance will be given to point-of-care PCR systems, such as Vivalytic, which provide rapid test results at the point of sample collection and are easy and intuitive to operate. This exclusive event will provide new insights into the "Third Pillar" of diagnostics. The panelists are proven experts in their field and will be sharing some experiential insights on the topic. Visitors can also attend the round table discussion to learn more about the innovative Vivalytic system and the challenges of the diagnostics sector at the point of care.

Related Links:
Bosch Healthcare Solutions

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more